Search our Database of Scientific Publications and Authors

I’m looking for a

    4134 results match your criteria Biology of Blood and Marrow Transplantation[Journal]

    1 OF 83

    Validation of the Revised PAM Score in Patients with AML Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
    Biol Blood Marrow Transplant 2018 May 21. Epub 2018 May 21.
    Universitätsklinikum Carl Gustav Carus der TU Dresden, Medizinische Klinik und Poliklinik I, Dresden, Germany; DKMS Clinical Trials Unit, Dresden, Germany.
    Purpose: Despite recent advances, allogeneic hematopoietic stem cell transplantation (alloHSCT) continues to be accompanied by a high rate of morbidity and mortality. Several scores have been developed to predict outcome after HSCT. The PAM score has been recently revised, and utilizes information on patient age, donor type, disease risk, cytomegalovirus (CMV) serostatus of patients and donors, and the forced expiratory volume in one second (FEV1). Read More

    Single Ultra-High Dose Cholecalciferol to Prevent Vitamin D Deficiency in Pediatric Hematopoietic Stem Cell Transplantation.
    Biol Blood Marrow Transplant 2018 May 18. Epub 2018 May 18.
    Division of Endocrinology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center and University of Cincinnati, Cincinnati, OH, USA. Electronic address:
    Background: Vitamin D (vitD) deficiency is prevalent among childhood hematopoietic stem cell transplantation (HSCT) recipients and associated with inferior transplant survival at 100 days after transplantation. Achieving and maintaining therapeutic vitD levels in HSCT recipients is extremely challenging in the first 3-6 months after transplant due to poor compliance in the setting of mucositis, and concomitant use of critical transplant drugs that interfere with vitD absorption. We sought to evaluate the safety and efficacy of a single, ultra-high dose of vitD given prior to childhood HSCT to maintain levels in a therapeutic range during the peri-transplantation period. Read More

    Comparative Efficacy and Safety of Different Antiviral Agents for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic-Cell Transplantation: a Systematic Review and Meta-Analysis.
    Biol Blood Marrow Transplant 2018 May 16. Epub 2018 May 16.
    Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Electronic address:
    Over the past 25 years, several randomized controlled trials have investigated the efficacy of different antiviral agents for cytomegalovirus (CMV) prophylaxis in allogeneic hematopoietic-cell transplantation. We performed a systematic literature review, conventional meta-analysis and network meta-analysis using a random-effects model and risk ratios (RR) with corresponding 95% confidence intervals (CI) as effect estimates. Fifteen randomized controlled trials were identified, including seven different antiviral agents: acyclovir, ganciclovir, maribavir, brincidofovir, letermovir, valacyclovir, and vaccine. Read More

    Antibiotic Exposure Prior to Respiratory Viral Infection is Associated with Progression to Lower Respiratory Tract Disease in Allogeneic Hematopoietic Cell Transplant Recipients.
    Biol Blood Marrow Transplant 2018 May 16. Epub 2018 May 16.
    Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.; Department of Medicine, University of Washington, Seattle, WA, USA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. Electronic address:
    Introduction: Recent publications note an association between antibiotic exposure and respiratory viral infections (RVIs). Antibiotics affect microbiota and impair immune response against RVIs in mice, and low microbiome diversity is associated with pulmonary complications including viral lower respiratory tract disease (LRTD) in hematopoietic cell transplantation (HCT) recipients. In this study, we examined whether antibiotic exposure was associated with increased risk of disease progression in RVIs post-transplantation. Read More

    Cardiac Profile of Chimeric Antigen Receptor (CAR) T-Cell Therapy in Children: a Single Institution Experience.
    Biol Blood Marrow Transplant 2018 May 14. Epub 2018 May 14.
    Division of Pediatric Cardiology, Children's Hospital of Philadelphia, PA.
    Background: Immunotherapy with chimeric antigen receptor (CAR)-modified T-cells targeting CD19 for pediatric acute lymphoblastic leukemia (ALL) has demonstrated significant efficacy. The principle toxicity is cytokine release syndrome with resultant hypotension. However, the spectrum of cardiovascular effects associated with CAR T-cell therapy has not been systematically evaluated. Read More

    Allogeneic Stem Cell Transplantation From HLA-Mismatched Donors for Pediatric Patients with Acute Lymphoblastic Leukemia Treated According to the 2003 BFM and 2007 International-BFM Studies: Impact of Disease Risk on Outcomes.
    Biol Blood Marrow Transplant 2018 May 14. Epub 2018 May 14.
    St Anna Children's Hospital, Universitätsklinik für Kinder- und Jugendheilkunde, Medizinische Universität Wien, Vienna, Austria.
    Rational: Allogeneic HSCT is beneficial for pediatric patients with relapsed or (very) high-risk ALL in remission. A total of 1115 consecutive patients were included in the ALL SCT 2003 BFM study and the ALL SCT 2007-International study and were stratified according to relapse risk (Standard vs. High vs. Read More

    A Couple-Based Communication Intervention for Hematopoietic Cell Transplant Survivors and Their Caregiving Partners: Feasibility, Acceptability, and Change in Process Measures.
    Biol Blood Marrow Transplant 2018 May 14. Epub 2018 May 14.
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
    Hematopoietic cell transplantation (HCT) poses significant challenges for recipients and their caregiving partners. Couples may refrain from talking about treatment-related fears and concerns in order to minimize distress. This single-group, pre-post study examined feasibility and acceptability of an intervention designed to optimize communication between HCT patients and partners; it also assessed change in process measures. Read More

    Unmanipulated Haploidentical Hematopoietic Stem Cell Transplantation Achieved Outcomes Comparable with Matched Unrelated Donor Transplantation in Young Acquired Severe Aplastic Anemia.
    Biol Blood Marrow Transplant 2018 May 14. Epub 2018 May 14.
    Department of Bone Marrow Transplantation, Hebei Yanda Lu Daopei Hospital, Langfang,China. Electronic address:
    Salvage haploidentical HSCT is considered in patients with severe aplastic anemia (SAA) if matched unrelated donor (MUD) is unavailable. However, studies on haplo- and MUD transplantation in SAA are yet lacking. The present study retrospectively analyzed the outcomes of 89 young SAA patients who underwent unmanipulated alternative hematopoietic stem cell transplantation (HSCT) between September 2012 and September 2016 at our single center. Read More

    Impact of Thrombotic Microangiopathy on Renal Outcomes and Survival after Hematopoietic Stem Cell Transplantation.
    Biol Blood Marrow Transplant 2018 May 11. Epub 2018 May 11.
    Transplantation Research Center, Brigham and Women's Hospital, Boston, MA; Division of Renal Medicine, Brigham and Women's Hospital, Boston, MA. Electronic address:
    Transplantation-associated thrombotic microangiopathy (TA-TMA) is a serious complication of hematopoietic stem cell transplantation (HSCT). We characterized the incidence, risk factors, and long-term outcomes associated with TA-TMA by performing a comprehensive review of all adult patients (n=1,990) undergoing allogeneic HSCT at the Dana Farber Cancer Institute/Brigham and Women's Hospital between 2005 and 2013. Using the City of Hope criteria, we identified 258 (13%) and 508 (26%) patients with "definite" and "probable" TMA, respectively. Read More

    Phase I Trial of Brentuximab Vedotin for Steroid-Refractory Chronic Graft-Versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation.
    Biol Blood Marrow Transplant 2018 May 11. Epub 2018 May 11.
    Blood and Marrow Transplant Program, Massachusetts General Hospital, Boston, MA. Electronic address:
    We conducted a phase I study of brentuximab vedotin (BV), an antibody-drug conjugate targeting CD30, for the treatment of steroid-refractory chronic graft-versus-host disease (cGVHD). A modified 3+3 study design was used with the primary endpoint to determine the maximum tolerated dose (MTD) of BV in this population. Escalating doses of BV were planned, starting with 0. Read More

    Platelet Transfusion Refractoriness in Single-Unit Cord Blood Transplantation for Adults: Risk Factors and Clinical Outcomes.
    Biol Blood Marrow Transplant 2018 May 10. Epub 2018 May 10.
    Department of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
    Platelet transfusion refractoriness (PTR) is frequently observed after allogeneic hematopoietic cell transplantation (HCT). However, the incidence of and risk factors for PTR, and impact of PTR on transplant outcomes after cord blood transplantation (CBT) have not been fully investigated. We retrospectively analyzed 185 adult patients who received single-unit CBT in our institute. Read More

    Wilms' Tumor 1 (WT1) Expression Using a Standardized European Leukemia Net-Certified Assay Compared to Other Methods for Detection of Minimal Residual Disease in MDS and AML Patients after Allogeneic Blood Stem Cell Transplantation.
    Biol Blood Marrow Transplant 2018 May 10. Epub 2018 May 10.
    Department of Hematology, Oncology and Clinical Immunology, University of Duesseldorf, Medical Faculty, Duesseldorf, Germany. Electronic address:
    Overexpressed Wilms' Tumor 1 (WT1) gene is informative in many patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) and is measurable in peripheral blood (PB). Despite these advantages WT1 has not broadly been established as marker for minimal residual disease (MRD) monitoring after allogeneic transplantation (allo-HSCT) due to limited patient numbers, differing sample sources and non-standardized in-house methods. To estimate its value as MRD marker we serially quantified PB WT1 expression using a standardized European Leukemia Net-certified assay in 59 patients with AML and MDS after allo-HSCT. Read More

    Status of NK Cell Recovery in Day 21 Bone Marrow after Allogeneic Hematopoietic Stem Cell Transplantation Predicts Clinical Outcome.
    Biol Blood Marrow Transplant 2018 May 10. Epub 2018 May 10.
    Division of Hematology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.
    Rapid immune recovery following allogeneic hematopoietic stem cell transplantation (allo-HSCT) is important for clinical outcome prediction. In most studies, immune recovery after allo-HSCT has been monitored via peripheral blood. However, few reports regarding the status of absolute lymphocyte subsets in the bone marrow (BM) microenvironment have been undertaken. Read More

    A Modified Intensive Strategy to Prevent CMV Disease in Seropositive Umbilical Cord Blood Transplant Recipients.
    Biol Blood Marrow Transplant 2018 May 10. Epub 2018 May 10.
    Department of Medicine, University of Washington, Seattle, WA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
    We previously demonstrated a lower rate of CMV reactivation and disease among seropositive umbilical cord blood transplant (CBT) recipients receiving an intensive prophylaxis strategy consisting of ganciclovir on days -8 to -2 pre-transplant, high-dose valacyclovir post-transplant, and twice-weekly serum CMV PCR testing. We hypothesized that a modified intensive strategy excluding pre-transplant ganciclovir would be similarly effective. We compared the risk of CMV reactivation, occurrence of CMV disease, and duration of anti-CMV therapy by day 100 post-CBT in patients receiving the modified intensive and intensive strategies. Read More

    Baseline Renal Function and Albumin are Powerful Predictors for Allogeneic Transplantation-Related Mortality.
    Biol Blood Marrow Transplant 2018 May 9. Epub 2018 May 9.
    Department of Hematology, Erasmus University Medical Center, Rotterdam, the Netherlands.
    Rationale: Biomarkers measured in blood chemistry before allogeneic hematopoietic stem cell transplantation (HSCT) may reflect patients' physiological status. We hypothesized that selected markers are predictive for non-relapse mortality (NRM) following transplantation and could contribute to risk assessment.

    Patients And Methods: We investigated the value of pre-HSCT albumin, estimated glomerular filtration rate (eGFR) and alkaline phosphatase (AlkP) in predicting NRM. Read More

    Steroid's Deleterious Effect on CMV Infection Rate Post-Allo-SCT Depends on Pre-Transplant CMV Serostatus of Donors and Recipients.
    Biol Blood Marrow Transplant 2018 May 9. Epub 2018 May 9.
    Hematology Department, Hospital Clínic Barcelona, Barcelona, Spain; Institut d'Investigació Biomèdica August Pi I Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain; Institut Josep Carreras.
    This study examined the impact of prednisone (PDN) on CMV infection after allogeneic stem cell transplantation (allo-SCT) according to donor (D) and recipient (R) CMV serostatus. Seventy-five patients underwent allo-SCT from June 2010 to July 2012. The risk of CMV infection according to D and R serostatus was defined as follows: high risk (HR) (D-/R+), intermediate risk (IR) (D+/R+ and D+/R-) and low risk (LR) (D-/R-). Read More

    Engagement with INSPIRE, an Online Program for Hematopoietic Cell Transplantation Survivors.
    Biol Blood Marrow Transplant 2018 May 9. Epub 2018 May 9.
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
    In a secondary analysis of a randomized controlled trial (RCT), we examined participants' engagement with INSPIRE, a personalized online program for hematopoietic cell transplantation (HCT) survivors that focuses on cancer-related distress, depression, fatigue, and health care needs. We approached all adult, 3- to 18-year HCT survivors treated for hematologic malignancy without relapse or second cancer in the previous 2 years for participation in an RCT with either immediate or delayed access to INSPIRE. Participants with immediate access could view the online material at any time. Read More

    Defining Incidence and Risk Factors for Catheter Associated Bloodstream Infections in an Outpatient Adult Hematopoietic Cell Transplant Program.
    Biol Blood Marrow Transplant 2018 May 9. Epub 2018 May 9.
    Division of Infectious Diseases, Department of Internal Medicine, Vanderbilt University Medical Center, Nashville, TN.
    Background: Allogeneic hematopoietic cell transplant (HCT) patients are at an increased risk of developing central line-associated bloodstream infections (CLABSIs) due to prolonged periods of myelosuppression, immunosuppression, and indwelling catheter days. CLABSIs are among the most serious complications in HCT recipients and can lead to prolonged hospitalizations, intensive care unit (ICU) admissions, lengthy antimicrobial therapies, and increased mortality. There is a lack of data regarding the incidence and risk factors associated with the development of CLABSIs in the HCT population undergoing outpatient transplantation. Read More

    Melphalan-Based Reduced Intensity Conditioning is Associated with Favorable Disease Control and Acceptable Toxicities in Patients Older Than 70 with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
    Biol Blood Marrow Transplant 2018 May 9. Epub 2018 May 9.
    Department of Hematology and Hematopoietic Stem Cell Transplantation, City of Hope, Duarte, CA.
    Allogeneic hematopoietic stem cell transplantation (AlloHCT) is offered increasingly to elderly patients with hematologic malignancies. However, outcome data in those who are 70 years or older are limited, and no standard conditioning regimen has been established for this population. In this retrospective study, we evaluated the outcome of 53 consecutive patients aged 70 years and older who underwent AlloHCT with melphalan (Mel)-based reduced-intensity conditioning (RIC) at City of Hope. Read More

    Treosulfan, Fludarabine, and Low-Dose Total Body Irradiation for Children and Young Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation: Prospective Phase II Trial of the Pediatric Blood and Marrow Transplant Consortium.
    Biol Blood Marrow Transplant 2018 May 9. Epub 2018 May 9.
    Fred Hutchinson Cancer Research Center and University of Washington, Seattle, Washington.
    This multicenter study evaluated a treosulfan-based regimen in children and young adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) undergoing allogeneic hematopoietic cell transplant (HCT). Forty patients with median age 11 years (range, 1 to 19) underwent allogeneic HCT for AML in first (n = 18), second (n = 11), and third or greater remission (n = 3) or MDS (n = 8) using bone marrow (n = 25), peripheral blood stem cells (n = 5), or cord blood (n = 9). The regimen consisted of body surface area (BSA)-based treosulfan 10 g/m/day (BSA ≤ . Read More

    Antiviral T Cells for Adenovirus in the Pretransplant Period: A Bridge Therapy for Severe Combined Immunodeficiency.
    Biol Blood Marrow Transplant 2018 May 9. Epub 2018 May 9.
    Center for Cancer and Immunology Research, Children's National Health System, Washington, DC; Division of Allergy & Immunology, Children's National Health System, Washington, DC. Electronic address:
    Viral infections can be life threatening in patients with severe combined immunodeficiency (SCID) and other forms of profound primary immunodeficiency disorders both before and after hematopoietic stem cell transplantation (HSCT). Adoptive immunotherapy with virus-specific T cells (VSTs) has been utilized in many patients in the setting of HSCT, but has very rarely been attempted for treatment of viral infections before HSCT. Here we describe the use of VSTs in an infant with RAG1 SCID who had developed disseminated adenovirus which failed to improve on cidofovir. Read More

    Pharmacokinetics of High-Dose Propylene Glycol-Free Melphalan in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation.
    Biol Blood Marrow Transplant 2018 May 8. Epub 2018 May 8.
    Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin. Electronic address:
    High-dose melphalan followed by autologous stem cell transplant (ASCT) is standard of care for eligible patients with multiple myeloma (MM). Evomela (propylene glycol-free melphalan HCl [PG-Free Mel]; Spectrum Pharmaceuticals, Irvine, CA) was approved by the US Food and Drug Administration as conditioning therapy for ASCT in MM in 2 daily 100-mg/m doses for a total dose of 200 mg/m. In this phase II, open-label study PG-Free Mel (Evomela) conditioning was given at single dose of 200 mg/m on day -2 pre-ASCT to establish pharmacokinetic (PK) parameters and safety. Read More

    Evaluation of HistoCheck as a Predictor of Clinical Outcomes after Haploidentical Hematopoietic Stem Cell Transplantation.
    Biol Blood Marrow Transplant 2018 May 8. Epub 2018 May 8.
    Peking University People's hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China; Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, China. Electronic address:
    Haploidentical hematopoietic stem cell transplantation (haplo-HSCT) is available for nearly all patients without matching human leukocyte antigen (HLA) related or unrelated donors. There was not a valid evaluation system to predict the most proper donor. HistoCheck was based on the functional similarity of amino acids to estimate the allogenicity of HLA mismatches with a sequence similarity matching (SSM) score. Read More

    Very Low Numbers of CD4 FoxP3 Regulatory T Cells Expanded in Donors via TL1A-Ig and Low-Dose IL-2 Exhibit a Distinct Activation and Functional Profile and Suppress Graft-versus-Host Disease in a Preclinical Model.
    Biol Blood Marrow Transplant 2018 May 8. Epub 2018 May 8.
    Department of Microbiology and Immunology, Miller School of Medicine, University of Miami, Miami, Florida; Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, Florida; Department of Medicine, Miller School of Medicine, University of Miami, Miami, Florida; Department of Ophthalmology, Miller School of Medicine, University of Miami, Miami, Florida. Electronic address:
    Regulatory T cells (Tregs) are essential for the maintenance of tolerance and immune homeostasis. In allogeneic hematopoietic stem cell transplantation (aHSCT), transfer of appropriate Treg numbers is a promising therapy for the prevention of graft-versus-host disease (GVHD). We have recently reported a novel approach that induces the marked expansion and selective activation of Tregs in vivo by targeting tumor necrosis factor receptor superfamily 25 (TNFRSF25) and CD25. Read More

    Ambulatory Blood Pressure and Endothelial Dysfunction in Hematopoietic Cell Transplantation Recipients.
    Biol Blood Marrow Transplant 2018 Apr 25. Epub 2018 Apr 25.
    University of Washington and Seattle Children's Hospital; Fred Hutchinson Cancer Research Center, Clinical Research Division. Electronic address:
    Hematopoietic cell transplantation (HCT) is a common treatment for many disorders. Albuminuria post-HCT, which may represent endothelial injury or inflammation from graft- versus-host disease, increases the risk of chronic kidney disease and nonrelapse mortality at 1 year. HCT recipients also have abnormal blood pressure (BP) and increased rates of cardiovascular complications. Read More

    Impact of an Additional Chromosome on the Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Philadelphia Chromosome-Positive Acute Myeloid Leukemia in Adults.
    Biol Blood Marrow Transplant 2018 Apr 23. Epub 2018 Apr 23.
    Department of Hematology, Leukemia Research Institute, Seoul St. Mary's Hematology Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
    The incidence of Philadelphia chromosome positivity (Ph) in adults with acute myeloid leukemia (AML) is very low. Ph AML is considered to be high risk for failure to attain remission or for early relapse after standard chemotherapy. Because of the low incidence of the disease, it has been difficult to determine the best treatment, including the effects of tyrosine kinase inhibitors. Read More

    Human Herpesvirus-6B Reactivation Is a Risk Factor for Grades II to IV Acute Graft-versus-Host Disease after Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis.
    Biol Blood Marrow Transplant 2018 Apr 21. Epub 2018 Apr 21.
    Center for Clinical and Translational Research, Seattle Children's Research Institute, Seattle, Washington; Department of Pediatrics, University of Washington, Seattle, Washington. Electronic address:
    Graft-versus-host disease (GVHD) is an important cause of morbidity and mortality after allogeneic hematopoietic cell transplantation (HCT). Many studies have suggested that human herpesvirus-6B (HHV-6B) plays a role in acute GVHD (aGVHD) after HCT. Our objective was to systematically summarize and analyze evidence regarding HHV-6B reactivation and development of aGVHD. Read More

    Eltrombopag for the Treatment of Refractory Pure RBC Aplasia after Major ABO Incompatible Hematopoietic Stem Cell Transplantation.
    Biol Blood Marrow Transplant 2018 Apr 21. Epub 2018 Apr 21.
    A.O.U. Città della Salute e della Scienza, Dipartimento di Oncologia, SSD Trapianto allogenico di cellule staminali, Turin, Italy.
    Pure RBC aplasia (PRCS) is a well-recognized complication after allogeneic hematopoietic stem cell transplantation (HSCT). Many therapeutic options are available to treat this condition, including erythropoietin, rituximab, bortezomib, plasma exchange, immunoadsorption, donor lymphocyte infusion, mesenchymal stem cells, antithymocyte globulin, and high-dose steroids; however, treatment outcomes are often variable and can sometimes lead to disappointing results. In this brief article we report our experience with 2 patients with PRCA after major ABO-incompatible HSCT who were resistant to multiple therapeutic interventions and who eventually benefited from treatment with eltrombopag, a thrombopoietin mimetic approved by the US Food and Drug Administration for the treatment of patients with immune thrombocytopenic purpura or severe aplastic anemia refractory to immunosuppressive agents or not eligible for HSCT. Read More

    Thiotepa-Based Intensified Reduced-Intensity Conditioning Adult Double-Unit Cord Blood Hematopoietic Stem Cell Transplantation Results in Decreased Relapse Rate and Improved Survival Compared with Transplantation Following Standard Reduced-Intensity Conditioning: A Retrospective Cohort Comparison.
    Biol Blood Marrow Transplant 2018 Apr 21. Epub 2018 Apr 21.
    Division of Hematology, University of Colorado Denver, Denver, Colorado. Electronic address:
    The "Minnesota" reduced-intensity conditioning (RIC) cord blood transplantation (CBT) regimen (standard RIC) of fludarabine (Flu) (200 mg/m), cyclophosphamide (Cy) (50 mg/kg), and 200- or 300-cGy total body irradiation (TBI) is the most published RIC CBT regimen. Though well tolerated, high relapse rates remain a concern with this regimen. Intensification of conditioning may reduce relapse without increasing transplant-related mortality (TRM). Read More

    Deep NPM1 Sequencing Following Allogeneic Hematopoietic Cell Transplantation Improves Risk Assessment in Adults with NPM1-Mutated AML.
    Biol Blood Marrow Transplant 2018 Apr 21. Epub 2018 Apr 21.
    Department of Laboratory Medicine, Division of Hematopathology, University of Washington, Seattle, Washington.
    Relapse is the major cause of death in patients with acute myelogenous leukemia (AML) after allogeneic hematopoietic cell transplantation (HCT). Measurable residual disease (MRD) detected by multiparameter flow cytometry (MFC) before and after HCT is a strong, independent risk factor for relapse. As next-generation sequencing (NGS) is increasingly applied in AML MRD detection, it remains to be determined if NGS can improve prediction of post-HCT relapse. Read More

    Long-Term Results of Prophylactic Donor Lymphocyte Infusions for Patients with Multiple Myeloma after Allogeneic Stem Cell Transplantation.
    Biol Blood Marrow Transplant 2018 Apr 21. Epub 2018 Apr 21.
    Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Electronic address:
    The major reason for treatment failure after allografting in multiple myeloma (MM) is relapse. Donor lymphocyte infusions (DLIs) are considered a valuable post-transplant strategy mainly for relapsed patients but using them to prevent relapse in MM has been reported rarely. In the present study, we examined the efficacy of prophylactic DLIs after allogeneic hematopoietic stem cell transplantation (allo-HSCT) in myeloma patients with a long-term follow-up of more than 5 years. Read More

    Bone Marrow Transplantation after Nonmyeloablative Treosulfan Conditioning Is Curative in a Murine Model of Sickle Cell Disease.
    Biol Blood Marrow Transplant 2018 Apr 21. Epub 2018 Apr 21.
    Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama. Electronic address:
    Allogeneic hematopoietic stem cell transplantation (HSCT) can be curative for patients with sickle cell disease (SCD). However, morbidity associated with myeloablative conditioning and graft-versus-host disease has limited its utility. To this end, autologous HSCT for SCD using lentiviral gene-modified bone marrow (BM) or peripheral blood stem cells has been undertaken, although toxicities of fully ablative conditioning with busulfan and incomplete engraftment have been encountered. Read More

    Peripheral Blood Grafts for T Cell-Replete Haploidentical Transplantation Increase the Incidence and Severity of Cytokine Release Syndrome.
    Biol Blood Marrow Transplant 2018 Apr 19. Epub 2018 Apr 19.
    Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.
    T cell-replete post-transplant cyclophosphamide (PTCy)-based protocols have led to increasing use of haploidentical allogeneic hematopoietic cell transplantation (haploHCT). With this approach, bidirectional alloreactivity causing nonengraftment or severe graft-versus-host disease (GVHD) is no a longer major barrier to haploHCT. PTCy eliminates alloreactive lymphocytes but spares CD34 stem cells and regulatory T lymphocytes, resulting in reliable hematopoietic recovery with relatively low incidence of GVHD. Read More

    Safety and Efficacy of Once-Daily Intravenous Busulfan in Allogeneic Transplantation: A Matched-Pair Analysis.
    Biol Blood Marrow Transplant 2018 Apr 19. Epub 2018 Apr 19.
    Division of Hematology, Saitama Medical Center, Jichi Medical University, Saitama, Japan; Division of Hematology, Department of Medicine, Jichi Medical University, Shimotsuke, Japan. Electronic address:
    Compared with 4-times-daily infusion of intravenous busulfan (ivBU4), the safety and efficacy of once-daily infusion of ivBU (ivBU1) has not been fully clarified. We have been routinely using ivBU1 in a conditioning regimen in adult patients with myeloid malignancy who undergo allogeneic hematopoietic stem cell transplantation. In this study, a total of 91 patients who received ivBU1 for 2 days (n = 18) or 4 days (n = 73) in our institutions were compared with 273 control patients who received ivBU4, who were matched for age, sex, performance status, disease risk, conditioning regimen, and donor type, selected from the database of the Japanese Society for Hematopoietic Cell Transplantation using optimal matching algorithms. Read More

    Distinctive Infectious Complications in Patients with Central Nervous System Lymphoma Undergoing Thiotepa, Busulfan, and Cyclophosphamide-Conditioned Autologous Stem Cell Transplantation.
    Biol Blood Marrow Transplant 2018 Apr 18. Epub 2018 Apr 18.
    Adult Bone Marrow Transplant (BMT) Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Medicine, Weill Cornell Medical College, New York, New York.
    We investigated the incidence of viral, fungal, bacterial, and parasitic infections observed in 57 patients with central nervous system lymphoma after thiotepa, busulfan, and cyclophosphamide-conditioned autologous stem cell transplantation (TBC-ASCT) and 79 patients with systemic non-Hodgkin lymphoma after traditional carmustine, etoposide, cytarabine, and melphalan-conditioned ASCT (BEAM-ASCT). Twenty of 57 (35%) TBC-ASCT patients had detectable viremia with human herpesvirus 6, cytomegalovirus, adenovirus, or BK virus, versus 9 of 79 (11%) BEAM-ASCT patients. Nine TBC-ASCT patients had clinically relevant viral infections (4 human herpesvirus 6, 2 cytomegalovirus, 1 adenovirus, 2 BK virus), versus 0 in the BEAM-ASCT group. Read More

    Efficacy of Cidofovir in Treatment of BK Virus-Induced Hemorrhagic Cystitis in Allogeneic Hematopoietic Cell Transplant Recipients.
    Biol Blood Marrow Transplant 2018 Apr 18. Epub 2018 Apr 18.
    Division of Hematology, Department of Medicine, London Health Sciences Centre, London, Ontario, Canada.
    BK virus-associated hemorrhagic cystitis (BK-HC) is a common complication after allogeneic hematopoietic stem cell transplantation (allo-HCT), with incidences up to 70%. Cidofovir is an antiviral agent with growing evidence as a therapeutic intervention. To assess the safety profile and efficacy of intravenous and intravesical cidofovir in allo-HCT patients with BK-HC, a retrospective study was undertaken of the allo-HCT cohort who received cidofovir for symptomatic BK-HC (hematuria with BK viruria or viremia) from January 2010 until March 2017 in a single transplant center in Ontario, Canada. Read More

    Extracorporeal Photopheresis Improves Survival in Hematopoietic Cell Transplant Patients with Bronchiolitis Obliterans Syndrome without Significantly Impacting Measured Pulmonary Functions.
    Biol Blood Marrow Transplant 2018 Apr 18. Epub 2018 Apr 18.
    Division of Hematology, Mayo Clinic, Rochester, Minnesota. Electronic address:
    We carried out the first matched retrospective cohort study aimed at studying the safety and efficacy of extracorporeal photopheresis (ECP) for bronchiolitis obliterans syndrome (BOS) after allogeneic hematopoietic cell transplantation (HCT). Medical records of 1325 consecutive adult patients who underwent HCT between 2005 and 2015 were reviewed. Seventy-four patients (median age, 51 years) with a diagnosis of BOS were included in the study. Read More

    Easy-to-Read Informed Consent Form for Hematopoietic Cell Transplantation Clinical Trials: Results from the Blood and Marrow Transplant Clinical Trials Network 1205 Study.
    Biol Blood Marrow Transplant 2018 Apr 18. Epub 2018 Apr 18.
    Cleveland Clinic, Cleveland, Ohio. Electronic address:
    Because of the complexity of hematopoietic cell transplant trial treatments, informed consent forms are often long and difficult to read. We evaluated a 2-column easy-to-read informed consent (ETRIC) form that incorporates elements of health literacy and readability in participants and centers participating in Blood and Marrow Transplant Clinical Trials Network (BMT CTN) clinical trials. In a randomized study 198 adult patients from 25 centers potentially eligible to participate in 4 BMT CTN interventional trials were randomized to the ETRIC form or a standard consent form for that trial. Read More

    Transplant Outcomes for Secondary Acute Myeloid Leukemia: Acute Leukemia Working Party of the European Society for Blood and Bone Marrow Transplantation Study.
    Biol Blood Marrow Transplant 2018 Apr 17. Epub 2018 Apr 17.
    EBMT Paris study office/CEREST-TC, Paris, France; Hematology Division, Chaim Sheba Medical Center, Tel Hashomer, Israel.
    Secondary acute myeloid leukemia (sAML) has been associated with inferior outcomes compared with de novo AML. Little is known about patient risk factors and outcomes in sAML after allogeneic hematopoietic stem cell transplantation (HCT); thus, this large systemic analysis of the European Society for Blood and Bone Marrow Transplantation registry was performed. This study included 4997 patients with sAML who received HCT from 2000 to 2016. Read More

    Comprehensive Analysis of the Activation and Proliferation Kinetics and Effector Functions of Human Lymphocytes, and Antigen Presentation Capacity of Antigen-Presenting Cells in Xenogeneic Graft-Versus-Host Disease.
    Biol Blood Marrow Transplant 2018 Apr 17. Epub 2018 Apr 17.
    Division of Hematology, Department of Medicine, Jichi Medical University, Shimotsuke, Japan. Electronic address:
    Xenogeneic graft-versus-host disease (GVHD) models in highly immunodeficient mice are currently being used worldwide to investigate human immune responses against foreign antigens in vivo. However, the individual roles of CD4 and CD8 T cells, and donor/host hematopoietic and nonhematopoietic antigen-presenting cells (APCs) in the induction and development of GVHD have not been fully investigated. In the present study, we comprehensively investigated the immune responses of human T cells and the antigen presentation capacity of donor/host hematopoietic and nonhematopoietic APCs in xenogeneic GVHD models using nonobese diabetic/Shi-scid-IL2rg mice. Read More

    Cost Effectiveness of Hematopoietic Stem Cell Transplantation Compared with Transfusion Chelation for Treatment of Thalassemia Major.
    Biol Blood Marrow Transplant 2018 Apr 16. Epub 2018 Apr 16.
    School of Public Health, Postgraduate Institute of Medical Education & Research, Chandigarh, India. Electronic address:
    Hematopoietic stem cell transplantation (HSCT) is the only cure for thalassemia major (TM), which inflicts a significant 1-time cost. Hence, it is important to explore the cost effectiveness of HSCT versus lifelong regular transfusion-chelation (TC) therapy. This study was undertaken to estimate incremental cost per quality-adjusted life-year (QALY) gained with the intervention group HSCT, and the comparator group TC, in TM patients. Read More

    Analysis of Clinical Factors and Outcomes Associated with Nonuse of Collected Peripheral Blood Stem Cells for Autologous Stem Cell Transplants in Transplant-Eligible Patients with Multiple Myeloma.
    Biol Blood Marrow Transplant 2018 Apr 12. Epub 2018 Apr 12.
    Division of Hematology, Mayo Clinic, Rochester, Minnesota. Electronic address:
    Collection and storage of peripheral blood stem cells (PBSCs) for use in autologous stem cell transplantation (ASCT) upon first disease relapse is an accepted practice for eligible patients with multiple myeloma (MM). However, little is known about the factors and outcomes associated with nonuse of these collected and stored PBSCs by MM patients who intended to have a delayed ASCT. From January 1, 2004 to December 31, 2014 we identified 342 patients who underwent collection and storage of their PBSCs in anticipation of a delayed ASCT upon first disease relapse. Read More

    Inosine Monophosphate Dehydrogenase Pharmacogenetics in Hematopoietic Cell Transplantation Patients.
    Biol Blood Marrow Transplant 2018 Apr 12. Epub 2018 Apr 12.
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
    We evaluated inosine monophosphate dehydrogenase (IMPDH) 1 and IMPDH2 pharmacogenetics in 247 recipient-donor pairs after nonmyeloablative hematopoietic cell transplant (HCT). Patients were conditioned with total body irradiation + fludarabine and received grafts from related or unrelated donors (10% HLA mismatch), with postgraft immunosuppression of mycophenolate mofetil (MMF) with a calcineurin inhibitor. Recipient and donor IMPDH genotypes (rs11706052, rs2278294, rs2278293) were not associated with day 28 T cell chimerism, acute graft-versus-host disease (GVHD), disease relapse, cytomegalovirus reactivation, nonrelapse mortality, or overall survival. Read More

    Haploidentical Peripheral Blood Stem Cell Transplantation Demonstrates Stable Engraftment in Adults with Sickle Cell Disease.
    Biol Blood Marrow Transplant 2018 Apr 12. Epub 2018 Apr 12.
    Division of Hematology & Oncology, Department of Medicine, Comprehensive Sickle Cell Center, University of Illinois at Chicago, Chicago, Illinois. Electronic address:
    We report on the screening and development of haploidentical hematopoietic stem cell transplantation (HSCT) for adult patients with clinically aggressive sickle cell disease (SCD) at our institution. Of 50 adult SCD patients referred for HSCT between January 2014 and March 2017, 20% were denied by insurance. Of 41 patients initially screened, 10% lacked an available haploidentical donor, 29% had elevated donor-specific antibodies (DSAs), and 34% declined to proceed to HSCT. Read More

    Late Effects Screening Guidelines after Hematopoietic Cell Transplantation (HCT) for Hemoglobinopathy: Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric HCT.
    Biol Blood Marrow Transplant 2018 Apr 10. Epub 2018 Apr 10.
    Pediatrics, UCSF Benioff's Children's Hospital, Oakland, California.
    Allogeneic hematopoietic cell transplantation (HCT) can halt organ damage and eliminate symptoms in hemoglobin disorders, including sickle cell disease (SCD) and thalassemia major. Managing the residual manifestations of pre-HCT disease complications and the long-term effects of HCT requires systematic monitoring, follow-up and intervention when indicated. Late complications vary with age and disease status at HCT and with transplant variables such as preparative regimen, donor source and compatibility, and immune reconstitution. Read More

    Varicella Zoster Virus Reactivation in Adult Survivors of Hematopoietic Cell Transplantation: How Do We Best Protect Our Patients?
    Biol Blood Marrow Transplant 2018 Apr 10. Epub 2018 Apr 10.
    Department of Allogeneic Stem Cell Transplantation, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden; Division of Hematology, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden.
    Reactivation of varicella zoster virus (VZV) remains a significant public health burden for long-term survivors of hematopoietic cell transplantation. Delayed immune reconstitution after transplantation due to immunosuppression, post-transplant therapies, poor engraftment, and graft-versus-host disease leave a large number of patients at risk for herpes zoster (shingles) and its highly morbid complications. Although prophylaxis with acyclovir or valacyclovir has reduced the incidence of VZV reactivation as long as prophylaxis is continued, the incidence of disease in the late post-transplant period or after stopping prophylaxis is greater in the hematopoietic cell transplantation population than the general public. Read More

    1 OF 83